Table of Contents Author Guidelines Submit a Manuscript
Scientifica
Volume 2014, Article ID 901586, 11 pages
http://dx.doi.org/10.1155/2014/901586
Review Article

Atrial Fibrillation: A Review of Recent Studies with a Focus on Those from the Duke Clinical Research Institute

Cardiology Division, Duke University Hospital, 2301 Erwin Road, DUMC 3845, Durham, NC 27710, USA

Received 24 February 2014; Accepted 24 June 2014; Published 19 August 2014

Academic Editor: Lei Xi

Copyright © 2014 Meena P. Rao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. Fuster, L. E. Ryden, and D. S. Cannom, “Acc/aha/esc 2006 guidelines for the management of patients with atrial fibrillation: a report of the american college of cardiology/american heart association task force on practice guidelines and the european society of cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the european heart rhythm association and the heart rhythm society,” Circulation, vol. 114, pp. e257–e354, 2006. View at Publisher · View at Google Scholar
  2. W. M. Feinberg, J. L. Blackshear, A. Laupacis, R. Kronmal, and R. G. Hart, “Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications,” Archives of Internal Medicine, vol. 155, no. 5, pp. 469–473, 1995. View at Publisher · View at Google Scholar · View at Scopus
  3. G. M. Novaro, C. R. Asher, D. L. Bhatt et al., “Meta-analysis comparing reported frequency of atrial fibrillation after acute coronary syndromes in asians versus whites,” The American Journal of Cardiology, vol. 101, no. 4, pp. 506–509, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. A. S. Go, E. M. Hylek, K. A. Phillips et al., “Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study,” Journal of the American Medical Association, vol. 285, no. 18, pp. 2370–2375, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. C. D. Furberg, B. M. Psaty, T. A. Manolio et al., “Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study),” The American Journal of Cardiology, vol. 74, no. 3, pp. 236–241, 1994. View at Publisher · View at Google Scholar · View at Scopus
  6. B. M. Psaty, T. A. Manolio, L. H. Kuller et al., “Incidence of and risk factors for atrial fibrillation in older adults,” Circulation, vol. 96, no. 7, pp. 2455–2461, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Miyasaka, M. E. Barnes, B. J. Gersh et al., “Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence,” Circulation, vol. 114, no. 2, pp. 119–125, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. E. J. Benjamin, D. Levy, S. M. Vaziri, R. B. D’Agostino, A. J. Belanger, and P. A. Wolf, “Independent risk factors for atrial fibrillation in a population-based Cohort: the Framingham heart study,” Journal of the American Medical Association, vol. 271, no. 11, pp. 840–844, 1994. View at Publisher · View at Google Scholar · View at Scopus
  9. P. A. Wolf, R. D. Abbott, and W. B. Kannel, “Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham study,” Archives of Internal Medicine, vol. 147, no. 9, pp. 1561–1564, 1987. View at Publisher · View at Google Scholar · View at Scopus
  10. P. A. Wolf, T. R. Dawber, H. E. Thomas Jr., and W. B. Kannel, “Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study,” Neurology, vol. 28, no. 10, pp. 973–977, 1978. View at Publisher · View at Google Scholar · View at Scopus
  11. K. M. Flegel, M. J. Shipley, and G. Rose, “Risk of stroke in non-rheumatic atrial fibrillation,” The Lancet, vol. 1, no. 8532, pp. 526–529, 1987. View at Google Scholar · View at Scopus
  12. H. J. Lin, P. A. Wolf, M. Kelly-Hayes et al., “Stroke severity in atrial fibrillation: the framingham study,” Stroke, vol. 27, no. 10, pp. 1760–1764, 1996. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Miyasaka, M. E. Barnes, K. R. Bailey et al., “Mortality Trends in Patients Diagnosed With First Atrial Fibrillation. A 21-Year Community-Based Study,” Journal of the American College of Cardiology, vol. 49, no. 9, pp. 986–992, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. E. J. Benjamin, P. A. Wolf, R. B. D’Agostino, H. Silbershatz, W. B. Kannel, and D. Levy, “Impact of atrial fibrillation on the risk of death: the Framingham heart study,” Circulation, vol. 98, no. 10, pp. 946–952, 1998. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Y. H. Lip, R. Nieuwlaat, R. Pisters, D. A. Lane, and H. J. G. M. Crijns, “Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation,” Chest, vol. 137, no. 2, pp. 263–272, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. Z. Hijazi, J. Oldgren, A. Siegbahn, C. B. Granger, and L. Wallentin, “Biomarkers in atrial fibrillation: a clinical review,” European Heart Journal, vol. 34, no. 20, pp. 1475–1480, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. Z. Hijazi, J. Oldgren, U. Andersson et al., “Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy,” Circulation, vol. 125, no. 13, pp. 1605–1616, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. Z. Hijazi, L. Wallentin, A. Siegbahn et al., “High sensitivity troponin-T and risk stratification in atrial fibrillation during treatment with apixaban or warfarin,” Journal of the American College of Cardiology, vol. 63, pp. 52–61, 2014. View at Publisher · View at Google Scholar
  19. S. H. Hohnloser, Z. Hijazi, L. Thomas et al., “Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial,” European Heart Journal, vol. 33, no. 22, pp. 2821–2830, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. Z. Hijazi, J. Oldgren, U. Andersson et al., “Cystatin C is prognostic for stroke, death and bleeding during anticoagulation of atrial fibrillation—a RELY substudy,” Circulation, vol. 124, Article ID A12492, 2011, (Abstract supplement AHA). View at Google Scholar
  21. C. J. Boos, R. A. Anderson, and G. Y. H. Lip, “Is atrial fibrillation an inflammatory disorder?” European Heart Journal, vol. 27, no. 2, pp. 136–149, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. D. S. G. Conway, P. Buggins, E. Hughes, and G. Y. H. Lip, “Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation,” American Heart Journal, vol. 148, no. 3, pp. 462–466, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Y. H. Lip, J. V. Patel, E. Hughes, and R. G. Hart, “High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis,” Stroke, vol. 38, no. 4, pp. 1229–1237, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. J. A. Nelson, J. P. Vavalle, C. H. May et al., “Warfarin use and long-term outcomes in patients with acute myocardial infarction and atrial fibrillation,” Journal of Thrombosis and Thrombolysis, pp. 1–7, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. C. N. Hess, S. Broderick, J. P. Piccini et al., “Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients,” American Heart Journal, vol. 164, no. 4, pp. 607–615, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. E. M. Hylek, C. Evans-Molina, C. Shea, L. E. Henault, and S. Regan, “Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation,” Circulation, vol. 115, no. 21, pp. 2689–2696, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. M. B. Sellers and L. K. Newby, “Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients,” American Heart Journal, vol. 161, no. 2, pp. 241–246, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. R. H. White, R. J. Beyth, H. Zhou, and P. S. Romano, “Major bleeding after hospitalization for deep-venous thrombosis,” The American Journal of Medicine, vol. 107, no. 5, pp. 414–424, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. S. D. Fihn, C. M. Callahan, D. C. Martin, M. B. McDonell, J. G. Henikoff, and R. H. White, “The risk for and severity of bleeding complications in elderly patients treated with warfarin,” Annals of Internal Medicine, vol. 124, no. 11, pp. 970–979, 1996. View at Publisher · View at Google Scholar · View at Scopus
  30. H. D. White, M. Gruber, J. Feyzi et al., “Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control results from SPORTIF III and V,” Archives of Internal Medicine, vol. 167, no. 3, pp. 239–245, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. R. G. Hart, L. A. Pearce, and M. I. Aguilar, “Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation,” Annals of Internal Medicine, vol. 146, no. 12, pp. 857–867, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. “The Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from 3 randomized trials,” Archives of Internal Medicine, vol. 157, no. 11, pp. 1237–1240, 1997. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Connolly, J. Pogue, R. Hart et al., “Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial,” The Lancet, vol. 367, no. 9526, pp. 1903–1912, 2006. View at Publisher · View at Google Scholar
  34. S. J. Connolly, J. Eikelboom, C. Joyner et al., “Apixaban in patients with atrial fibrillation,” The New England Journal of Medicine, vol. 364, no. 9, pp. 806–817, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Man-Son-Hing, G. Nichol, A. Lau, and A. Laupacis, “Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls,” Archives of Internal Medicine, vol. 159, no. 7, pp. 677–685, 1999. View at Publisher · View at Google Scholar · View at Scopus
  36. M. B. Leon, D. S. Baim, J. J. Popma et al., “A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting,” The New England Journal of Medicine, vol. 339, no. 23, pp. 1665–1671, 1998. View at Publisher · View at Google Scholar · View at Scopus
  37. S. D. Pokorney, M. W. Sherwood, and R. C. Becker, “Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation,” Journal of Thrombosis and Thrombolysis, vol. 36, no. 2, pp. 163–174, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Stangier, K. Rathgen, H. Stähle, D. Gansser, and W. Roth, “The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects,” British Journal of Clinical Pharmacology, vol. 64, no. 3, pp. 292–303, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. S. J. Connolly, M. D. Ezekowitz, S. Yusuf et al., “Dabigatran versus warfarin in patients with atrial fibrillation,” The New England Journal of Medicine, vol. 361, no. 12, pp. 1139–1151, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. M. R. Patel, K. W. Mahaffey, J. Garg et al., “Rivaroxaban versus warfarin in nonvalvular atrial fibrillation,” The New England Journal of Medicine, vol. 365, no. 10, pp. 883–891, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Weinz, T. Schwarz, D. Kubitza, W. Mueck, and D. Lang, “Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans,” Drug Metabolism and Disposition, vol. 37, no. 5, pp. 1056–1064, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. C. B. Granger, J. H. Alexander, J. J. V. McMurray et al., “Apixaban versus warfarin in patients with atrial fibrillation,” The New England Journal of Medicine, vol. 365, no. 11, pp. 981–992, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. N. Raghavan, C. E. Frost, Z. Yu et al., “Apixaban metabolism and pharmacokinetics after oral administration to humans,” Drug Metabolism and Disposition, vol. 37, no. 1, pp. 74–81, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. S. H. Hohnloser, J. Oldgren, S. Yang et al., “Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized evaluation of long-term anticoagulation therapy) trial,” Circulation, vol. 125, no. 5, pp. 669–676, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. K. A. A. Fox, J. P. Piccini, D. Wojdyla et al., “Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment,” European Heart Journal, vol. 32, no. 19, pp. 2387–2394, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. C. N. Hess, S. M. Al-Khatib, C. B. Granger, and R. Lopes, “A review of apixban for stroke prevention in atrial fibrillation: insights from ARISTOTLE,” Expert Review of Cardiovascular Therapy, vol. 11, no. 9, pp. 1105–1114, 2013. View at Google Scholar
  47. B. F. Gage, A. D. Waterman, W. Shannon, M. Boechler, M. W. Rich, and M. J. Radford, “Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation,” Journal of the American Medical Association, vol. 285, no. 22, pp. 2864–2870, 2001. View at Publisher · View at Google Scholar · View at Scopus
  48. G. Y. H. Lip, “Implications of the CHA2DS2-VASc and HAS-BLED scores for thromboprophylaxis in atrial fibrillation,” The American Journal of Medicine, vol. 124, no. 2, pp. 111–114, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. R. Pisters, D. A. Lane, R. Nieuwlaat, C. B. De Vos, H. J. G. M. Crijns, and G. Y. H. Lip, “A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart survey,” Chest, vol. 138, no. 5, pp. 1093–1100, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. R. D. Lopes, S. M. Al-Khatib, L. Wallentin et al., “Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial,” The Lancet, vol. 380, no. 9855, pp. 1749–1758, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. A. L. Dans, S. J. Connolly, L. Wallentin et al., “Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial,” Circulation, vol. 127, no. 5, pp. 634–640, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. J. H. Alexander, R. D. Lopes, S. James et al., “Apixaban with antiplatelet therapy after acute coronary syndrome,” The New England Journal of Medicine, vol. 365, no. 8, pp. 699–708, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. M. C. Bahit, R. D. Lopes, D. M. Wojdyla et al., “Apixaban in patients with atrial fibrillation and prior coronary disease: insights from the ARISTOTLE trial,” International Journal of Cardiology, vol. 170, no. 2, pp. 215–220, 2013. View at Google Scholar
  54. J. W. Eikelboom, S. J. Connolly, M. Brueckmann et al., “Dabigatran versus warfarin in patients with mechanical heart valves,” The New England Journal of Medicine, vol. 369, no. 13, pp. 1206–1214, 2013. View at Google Scholar
  55. J. Price, M. Hynes, M. Labinaz, M. Ruel, and M. Boodhwani, “Mechanical valve thrombosis with dabigatran,” Journal of the American College of Cardiology, vol. 60, no. 17, pp. 1710–1711, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Avezum, R. D. Lopes, P. J. Schulte et al., “Apixaban versus warfarin in patients with atrial fibrillation and valvular heart disease: findings from the ARISTOTLE study,” European Heart Journal, vol. 34, supplement 1, p. 809, 2013. View at Google Scholar
  57. L. Linkins, P. T. Choi, and J. D. Douketis, “Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis,” Annals of Internal Medicine, vol. 139, no. 11, pp. 893–900, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. D. A. Garcia, L. Wallentin, R. D. Lopes et al., “Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial,” American Heart Journal, vol. 166, pp. 549–558, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. L. Wallentin, S. Yusuf, M. D. Ezekowitz et al., “Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial,” The Lancet, vol. 376, no. 9745, pp. 975–983, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. L. Wallentin, R. D. Lopes, M. Hanna et al., “Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for Stroke prevention in atrial fibrillation,” Circulation, vol. 127, no. 22, pp. 2166–2176, 2013. View at Publisher · View at Google Scholar · View at Scopus
  61. http://www.boehringer-ingelheim.com/news/news_releases.html.
  62. I. M. Ogilvie, N. Newton, S. A. Welner, W. Cowell, and G. Y. H. Lip, “Underuse of oral anticoagulants in atrial fibrillation: a systematic review,” The American Journal of Medicine, vol. 123, no. 7, pp. 638.e4–645.e4, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. C. L. Garwood and T. L. Corbett, “Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls,” The Annals of Pharmacotherapy, vol. 42, no. 4, pp. 523–532, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. J. Healey, S. Connolly, Y. Yusuf et al., “Global variation in the etiology and management of atrial fibrillation: baseline results from a global atrial fibrillation registry (RELY),” Clinical Registry Highlight 1—Risk and Treatment Reality, Session # 711006, ESC, Paris, France, 2011.
  65. T. Wilke, A. Groth, S. Mueller et al., “Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients,” Thrombosis and Haemostasis, vol. 107, no. 6, pp. 1053–1065, 2012. View at Publisher · View at Google Scholar
  66. P. L. Hess, S. Kim, J. P. Piccini et al., “Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation,” The American Journal of Medicine, vol. 26, no. 7, pp. 625.e1–632.e1, 2013. View at Publisher · View at Google Scholar
  67. M. W. Cullen, S. Kim, J. P. Piccini Sr. et al., “Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry,” Circulation: Cardiovascular Quality and Outcomes, vol. 6, no. 4, pp. 461–469, 2013. View at Google Scholar
  68. B. A. Steinberg, S. Kim, J. P. Piccini et al., “Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation,” Circulation, vol. 128, no. 7, pp. 721–728, 2013. View at Publisher · View at Google Scholar
  69. K. He, J. M. Luettgen, D. Zhang et al., “Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor,” European Journal of Drug Metabolism and Pharmacokinetics, vol. 36, no. 3, pp. 129–139, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. R. P. Giugliano, C. T. Cuff, E. Braunwald et al., “Edoxaban versus warfarin in patients with atrial fibrillation,” The New England Journal of Medicine, vol. 368, no. 22, pp. 2093–2104, 2013. View at Google Scholar
  71. A. K. Kakkar, I. Mueller, J. P. Bassand et al., “Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the International, Observational, Prospective GARFIELD registry,” PloS ONE, vol. 8, no. 5, Article ID e63479, 2013. View at Google Scholar